Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients with Pre-Treated Advanced Gastric Cancer
Download PDF Read more
Category: Acad, Gov/Utilities
Illumina Wins Infringement Suit Against Premaitha Health plc and Ariosa Diagnostics, Inc.
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) announced today that the High Court of Justice, Chancery Division, Patents Court in the United Kingdom issued a judgment in its favor in the patent infringement suit filed against Premaitha Health plc, et al. and the patent infringement suit filed against Ariosa Diagnostics, Inc., et al. The Court found... Read more
FDA approves Roche’s Gazyva for previously untreated advanced follicular lymphoma
Basel, 17 November 2017 FDA approves Roche’s Gazyva for previously untreated advanced follicular lymphoma The first treatment option to demonstrate superior progression-free survival over standard-of-care Rituxan-based therapy Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in... Read more
FDA approves Roche’s Hemlibra (emicizumab-kxwh) for haemophilia A with inhibitors
Basel, 16 November 2017 FDA approves Roche’s Hemlibra (emicizumab-kxwh) for haemophilia A with inhibitors First new medicine in nearly 20 years to treat people with haemophilia A with inhibitors Hemlibra substantially reduced bleeds in adults and children Only medicine that can be self-administered once weekly by injection under the skin (subcutaneously) Roche (SIX: RO, ROG;... Read more
Shimadzu Supports New Medicinal Plant Chemistry Program at Northern Michigan University
November 14 2017 Shimadzu Scientific Instruments (SSI), the leading provider of cannabis testing instruments, and Northern Michigan University (NMU) announce a collaborative relationship in support of NMU’s new 4-year undergraduate degree program in Medicinal Plant Chemistry. This program is intended to complement the emerging cannabis economy with a specific focus on laboratory analysis, experimental horticulture,... Read more
Agilent Thought Leader Award Presented to Renowned Drug Discovery Researcher Professor Jiandong Jiang
Agilent Thought Leader Award Presented to Renowned Drug Discovery Researcher Professor Jiandong Jiang Award to Chinese Scientist Supports the Use of Various Molecular Approaches to Cancer Research SANTA CLARA, Calif., November 12, 2017 Agilent Technologies Inc. (NYSE: A) today announced that Professor Jiandong Jiang has received an Agilent Thought Leader Award in support of his... Read more
FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation
Basel, 07 November 2017 FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease Approval based on data from a basket study, which enrolls participants across multiple diseases based predominantly on genetic profile Roche (SIX: RO, ROG; OTCQX: RHHBY) announced... Read more
FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer
Basel, 07 November 2017 FDA approves Roche’s Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer Approval based on phase III results that showed Alecensa extended the average time that people lived without their disease worsening compared to crizotinib Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food... Read more
Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
Basel, 01 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia A with inhibitors will be featured New data for polatuzumab vedotin in a difficult-to-treat blood cancer, which led to... Read more
Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
Basel, 01 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia A with inhibitors will be featured New data for polatuzumab vedotin in a difficult-to-treat blood cancer, which led to... Read more